These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 3247701)

  • 21. [C-peptide determination in diabetics for the evaluation of insulin requirements].
    Keller U; Pasquel M; Berger W
    Schweiz Med Wochenschr; 1987 Feb; 117(6):187-92. PubMed ID: 3551060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overnight CSII as supplement to oral antidiabetic drugs in type 2 diabetes.
    Parkner T; Møller MK; Chen JW; Laursen T; Jørgensen C; Smedegaard JS; Lauritzen T; Christiansen JS
    Diabetes Obes Metab; 2008 Jul; 10(7):556-63. PubMed ID: 17593233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The importance of strict control of blood glucose at the onset and during the remission stage in newly diagnosed diabetic children].
    Vavrinec J; Lébl J; Zizkovský V; Dvorák P; Snajderová M
    Cesk Pediatr; 1988 May; 43(5):325-8. PubMed ID: 3042170
    [No Abstract]   [Full Text] [Related]  

  • 24. [Blood glucose, C-peptide and glucagon levels in patients with a labile course of diabetes mellitus during use of the device "Biostator"].
    Spesivtseva VG; Turova EA; Mamaeva GG; Sotnikova TI
    Probl Endokrinol (Mosk); 1985; 31(5):63-7. PubMed ID: 4070196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Does glycemic level influence the pharmacokinetics of an antibiotic (cefoperazone)?].
    Gin H; Demotes-Mainard F; Magimel S; Albin H; Morlat P; Aubertin J
    Diabete Metab; 1991; 17(4):417-20. PubMed ID: 1916000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical experience with optimized therapy of insulin dependent diabetes mellitus using NovoPen].
    Carta G; Borgoglio A; Borgoglio MG; Granata L; Cordera R; Adezati L
    Clin Ter; 1988 Feb; 124(4):315-20. PubMed ID: 2974343
    [No Abstract]   [Full Text] [Related]  

  • 27. [Regulation of the blood sugar level by the artificial endocrine pancreas (Biostator GCIIS) during dialysis of a diabetic patient].
    Bojta J; Juhász J; Bányai Z; Makó J; Tamás G
    Orv Hetil; 1979 Dec; 120(51):3109-10. PubMed ID: 396497
    [No Abstract]   [Full Text] [Related]  

  • 28. Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII.
    Koivisto VA; Yki-Järvinen H; Helve E; Karonen SL; Pelkonen R
    Diabetes; 1986 Jan; 35(1):78-82. PubMed ID: 3510143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rarity of a marked "dawn phenomenon" in diabetic subjects treated by continuous subcutaneous insulin infusion.
    Bending JJ; Pickup JC; Collins AC; Keen H
    Diabetes Care; 1985; 8(1):28-33. PubMed ID: 3971844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Occurrence of dawn phenomenon without change in insulin clearance in patients with insulin-dependent diabetes mellitus.
    Campbell PJ; Gerich JE
    Diabetes; 1986 Jul; 35(7):749-52. PubMed ID: 3522315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of insulin sensitivity on the occurrence of early-morning hyperglycemia in patients treated with insulin].
    Krzymień J; Szymerska E; Tracz M; Regulski M; Jasik M
    Pol Arch Med Wewn; 1989 Mar; 81(3):176-82. PubMed ID: 2697868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alterations in insulin clearance and hepatic blood flow during the night do not contribute to the 'dawn phenomenon' in type 1 diabetes.
    Widmer A; Keller U; Pasquel M; Berger W
    Horm Res; 1988; 29(5-6):197-201. PubMed ID: 3065206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The dawn phenomenon in diabetes mellitus].
    Shikano M
    Nihon Rinsho; 1991 Feb; 49 Suppl():563-9. PubMed ID: 2033851
    [No Abstract]   [Full Text] [Related]  

  • 34. Insulin clearance contributes to the variability of nocturnal insulin requirement in insulin-dependent diabetes mellitus.
    Dux S; White NH; Skor DA; Santiago JV
    Diabetes; 1985 Dec; 34(12):1260-5. PubMed ID: 3905459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Experience in the use of biostator in the treatment of diabetes mellitus in children of the pubertal age].
    Antsiferov MB; Karpova LA; Kolesnikova GS; Pankova SS; Starostina EG
    Pediatriia; 1989; (11):18-22. PubMed ID: 2608369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Occurrence of early-morning hyperglycemia (dawn phenomenon) in patients with diabetes mellitus type 1 and 2].
    Jasik M; Orłowska K
    Pol Arch Med Wewn; 1989 Apr; 81(4):207-13. PubMed ID: 2696935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dawn phenomenon in type 1 (insulin-dependent) diabetic adolescents: influence of nocturnal growth hormone secretion.
    Beaufrère B; Beylot M; Metz C; Ruitton A; François R; Riou JP; Mornex R
    Diabetologia; 1988 Aug; 31(8):607-11. PubMed ID: 3065115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Concentration of plasma testosterone in adult roosters of a low-weight strain].
    Kosutzký J; Bobáková E; Zeman M; Adamec O
    Vet Med (Praha); 1982 Apr; 27(4):209-16. PubMed ID: 6808749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Factors affecting stability in the course of insulin-dependent diabetes mellitus].
    Borisova AM; Koev D; Kirilov G
    Vutr Boles; 1989; 28(3):67-72. PubMed ID: 2672596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity.
    Perriello G; De Feo P; Torlone E; Fanelli C; Santeusanio F; Brunetti P; Bolli GB
    Diabetologia; 1991 Jan; 34(1):21-8. PubMed ID: 2055337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.